After 30 Years, Here's Biden's Plan To Lower Drug Costs: Negotiate
Aug 30, 2023
auto_awesome
White House correspondent Tamara Keith, White House reporter Deepa Shivaram, and Pharmaceuticals correspondent Sydney Lupkin discuss President Biden's plan to lower drug costs through negotiation, including the first 10 drugs for negotiation, barriers to lowering drug costs, and the potential impact on Medicare spending, support for negotiating drug prices, opposition from drug companies, and the plan's potential impact on different groups.
President Biden announced that Medicare will begin negotiating the prices of 10 commonly used drugs for older Americans, potentially lowering costs for seniors and gaining support from older voters in elections.
While the implementation of lower drug prices will take time and face opposition from the pharmaceutical industry, the negotiation of prescription drug prices has the potential to substantially reduce out-of-pocket expenses for Medicare recipients and benefit taxpayers as a whole.
Deep dives
Biden announces the negotiation of prescription drug prices for Medicare
President Biden announced that Medicare will begin negotiating the prices of 10 drugs that older Americans commonly use, including blood thinners, arthritis drugs, heart failure drugs, and cancer drugs. This move is significant as Medicare currently spends around $50 billion on these medications, out of a total spending of over $200 billion. The ability for the federal government to negotiate drug prices has long been a popular policy idea, but previous presidents were unable to accomplish this due to the powerful lobbying efforts of the pharmaceutical industry. Biden's announcement is expected to lower costs for seniors and gain support from older voters, who turn out reliably in elections.
The timeline for implementing lower drug prices and potential obstacles
While the announcement is a step in the right direction, the actual implementation of lower drug prices will take time. Companies have until October to agree to participate in negotiations and submit necessary data. Proposed prices will be given to the companies on February 1 of next year, followed by negotiations and the announcement of final negotiated prices in August. However, these new prices will not take effect until January 2026. Additionally, the pharmaceutical industry is strongly opposed to this policy and has filed eight lawsuits claiming violations of free speech and constitutional amendments. These lawsuits may prolong or even halt the process, as seen in previous legal battles over policy changes.
Impact of drug price negotiation on Medicare recipients and taxpayers
The negotiation of prescription drug prices will have a significant impact on Medicare recipients, specifically those who require expensive medications. Lower prices can substantially reduce out-of-pocket expenses for patients who rely on these drugs. Additionally, other Medicare beneficiaries who are not on these specific medications may also benefit from reduced monthly premiums, as the overall cost burden is distributed across all enrollees. Furthermore, this policy indirectly affects taxpayers, as Medicare is supported by taxpayer funding. Ultimately, the negotiation of drug prices has the potential to positively impact a wide range of people, including seniors, Medicare recipients, and taxpayers.
The government announced the first ten drugs that are the subject of price negotiations between the U.S. government and private companies. For decades, the government has been prohibited from negotiating the price it pays through Medicare for medication — until the rule was relaxed under the Affordable Care Act.
This episode: White House correspondent Tamara Keith, White House reporter Deepa Shivaram, and Pharmaceuticals correspondent Sydney Lupkin.
The podcast is produced by Elena Moore and Casey Morell. Our editor is Eric McDaniel. Our executive producer is Muthoni Muturi.
Unlock access to this and other bonus content by supporting The NPR Politics Podcast+. Sign up via Apple Podcasts or at plus.npr.org.